Long-acting risperidone: a review of its role in the treatment of bipolar disorder
Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.
Keywordsadherence bipolar disorder long-acting risperidone maintenance phase risperidone
Unable to display preview. Download preview PDF.
- 1.Goodwin FK, Jamison KR. Manic-Depressive Illness. 2nd edition. New York, NY: Oxford University Press; 2007.Google Scholar
- 15.Risperdal Consta (risperidone) long-acting injection. Prescribing information. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008.Google Scholar
- 17.Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75–84.CrossRefPubMedGoogle Scholar
- 25.Vieta E, Nieto E, Autet A, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008;23:1–6.Google Scholar
- 27.Kujawa M, Turner N, Turkoz I, et al. Frequently relapsing bipolar disorder: evidence for an effective treatment. Presented at: 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; Montreux, Switzerland; February 3–7, 2008.Google Scholar
- 28.Johnson & Johnson Pharmaceutical Research & Development, LLC. 2008. Clinical Trials website. A study of the safety and efficacy of injectable risperidone in the prevention of bipolar mood episodes (NCT00132678). Available at: http://clinicaltrials.gov/ct2/show/NCT00132678. Accessed October 15, 2008.
- 29.Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;635:384–390.Google Scholar
- 31.Freyberger HJ, Eerdekens M, Duchesne I, et al. Patient satisfaction with their medication during longacting risperidone injection. Int J Neuropsychopharmacol. 2002;5(suppl. 1):189. Abstract.Google Scholar
- 34.Young A, McElroy S, Olausson B, et al. Quetiapine monotherapy up to 52 weeks in patients with bipolar depression: continuation phase data from EMBOLDEN I & II. Presented at: 21st ENCP Conference; Barcelona, Spain; August 30–September 3, 2008.Google Scholar
- 37.Brecher M, Anderssen H, Paulsson P. Quetiapine in the maintenance treatment of bipolar I disorder: combined data from two long-term, phase III studies (NR 3-007). New Research Abstracts. Presented at: Annual Meeting of the American Psychiatric Association 2008; Washington, DC, USA; May 3, 2008.Google Scholar
- 38.Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–255.CrossRefPubMedGoogle Scholar
- 40.Kemp DE, Calabrese JR, Van-Tran Q, et al. Components of metabolic syndrome in patients enrolled in a clinical trial of aripiprazole for the maintenance treatment of bipolar disorder. Presented at: American College of Neuropsychopharmacology Annual Meeting; Boca Raton, FL; Dec. 9-13, 2007.Google Scholar
- 49.Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry. 2008;165:1420–1431.CrossRefPubMedGoogle Scholar
- 50.Clinical Trials website. A study to evaluate the effectiveness and safety of extended-release (ER) paliperidone compared with placebo in delaying the recurrence of symptoms in bipolar I disorder. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00490971?term=paliperidone+ER+bipolar&rank=3. Accessed December 21, 2008.